echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Express Advances Innovative Treatments for Multiple Myeloma, Sanofi and Blackstone Reach 300 Million Euro Partnership

    Express Advances Innovative Treatments for Multiple Myeloma, Sanofi and Blackstone Reach 300 Million Euro Partnership

    • Last Update: 2022-04-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎WuXi AppTec Content Team Editor On March 15, 2022, Sanofi and Blackstone Life Sciences announced a strategic collaboration
    .

    Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients
    .

    Sanofi will continue to fully manage the clinical program
    .

    If successful, Blackstone Life Sciences will be eligible to receive royalties on future product sales
    .

    The pivotal study is expected to begin in the second half of 2022
    .

    MM is the second most common hematological malignancy, with more than 130,000 new cases diagnosed globally each year
    .

    Despite available treatments, MM remains an incurable malignancy and is associated with a significant patient burden
    .

    Since there is no cure for MM, most patients relapse
    .

    Recurrent MM is when the cancer comes back after treatment or after a period of remission
    .

    Refractory MM is when the cancer does not respond or no longer responds to treatment
    .

    Sarclisa is a monoclonal antibody that specifically binds to the CD38 receptor expressed on MM cells
    .

    It acts through multiple mechanisms of action, including programmed tumor cell death (apoptosis) and immunomodulatory activity
    .

    CD38 is highly uniformly expressed on the surface of MM cells, making it a potential target for antibody-based therapeutics such as Sarclisa
    .

    In the development of subcutaneous formulations of Sarclisa, Sanofi has partnered with Enable Injections, an innovator in drug delivery technology, to advance the development of subcutaneous delivery of Sarclisa with the goal of providing a unique patient-centered therapeutic experience
    .

    To date, Sarclisa has been approved by various national and regional regulatory agencies and is used in combination with drugs such as lenalidomide, bortezomib, pomalidomide and dexamethasone in various The form is used in combination as a combination therapy and is used intravenously to treat certain patients with relapsing MM
    .

    "This collaboration with Blackstone will accelerate our ability to deliver this subcutaneously administered anti-CD38 antibody to patients, which we believe will provide patients with an innovative treatment that is more convenient," said Dr.
    John Reed, Sanofi's global head of research and
    development

    .

    References: [1] Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma.
    Retrieved March 15, 2022, from https:// releases/2022/2022-03-15-07-00-00-2403030 Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress

    .

    This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
    .

    This article is also not a treatment plan recommendation
    .

    For guidance on treatment options, please visit a regular hospital
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.